💊
Bosulif
bosutinib
Leukemia, Myeloid
✅ Authorised
✅
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
⚠️ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif